

Table 1.15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Both Sexes, 18 SEER Areas, 2010-2012

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	39.65	( 39.57, 39.74 )	39.83	( 39.74, 39.93 )	37.29	( 37.03, 37.54 )
Invasive and In Situ	42.00	( 41.91, 42.09 )	42.19	( 42.09, 42.29 )	38.62	( 38.36, 38.88 )
Oral Cavity and Pharynx	1.10	( 1.09, 1.12 )	1.15	( 1.13, 1.16 )	0.81	( 0.77, 0.84 )
Esophagus	0.50	( 0.49, 0.51 )	0.52	( 0.51, 0.53 )	0.44	( 0.41, 0.47 )
Stomach	0.85	( 0.84, 0.87 )	0.76	( 0.74, 0.77 )	1.06	( 1.01, 1.10 )
Colon and Rectum	4.51	( 4.48, 4.54 )	4.41	( 4.38, 4.44 )	4.76	( 4.67, 4.85 )
Invasive and In Situ	4.67	( 4.65, 4.70 )	4.56	( 4.53, 4.59 )	4.97	( 4.87, 5.07 )
Liver and Intrahepatic Bile Duct	0.91	( 0.90, 0.93 )	0.81	( 0.80, 0.83 )	0.96	( 0.92, 1.00 )
Pancreas	1.52	( 1.50, 1.54 )	1.50	( 1.48, 1.52 )	1.61	( 1.56, 1.67 )
Larynx	0.35	( 0.34, 0.36 )	0.36	( 0.35, 0.36 )	0.44	( 0.42, 0.47 )
Invasive and In Situ	0.38	( 0.37, 0.38 )	0.38	( 0.37, 0.39 )	0.47	( 0.44, 0.50 )
Lung and Bronchus	6.57	( 6.53, 6.61 )	6.72	( 6.68, 6.76 )	6.36	( 6.25, 6.47 )
Melanoma of the Skin	2.09	( 2.07, 2.11 )	2.45	( 2.42, 2.47 )	0.11	( 0.09, 0.12 )
Invasive and In Situ	3.54	( 3.52, 3.57 )	4.04	( 4.01, 4.07 )	0.14	( 0.13, 0.16 )
Breast	6.37	( 6.34, 6.40 )	6.46	( 6.42, 6.50 )	5.97	( 5.87, 6.07 )
Invasive and In Situ	7.56	( 7.53, 7.60 )	7.63	( 7.59, 7.67 )	7.15	( 7.05, 7.26 )
Urinary Bladder (Invasive and In Situ)	2.41	( 2.39, 2.43 )	2.62	( 2.59, 2.64 )	1.28	( 1.23, 1.34 )
Kidney and Renal Pelvis	1.60	( 1.59, 1.62 )	1.65	( 1.64, 1.67 )	1.59	( 1.54, 1.64 )
Brain and Other Nervous System	0.61	( 0.60, 0.62 )	0.68	( 0.66, 0.69 )	0.35	( 0.33, 0.38 )
Thyroid	1.15	( 1.14, 1.17 )	1.21	( 1.20, 1.23 )	0.66	( 0.64, 0.69 )
Hodgkin Lymphoma	0.22	( 0.21, 0.22 )	0.23	( 0.23, 0.24 )	0.19	( 0.18, 0.21 )
Non-Hodgkin Lymphoma	2.12	( 2.10, 2.14 )	2.22	( 2.20, 2.24 )	1.30	( 1.26, 1.35 )
Myeloma	0.74	( 0.73, 0.75 )	0.68	( 0.67, 0.69 )	1.27	( 1.23, 1.32 )
Leukemia	1.47	( 1.46, 1.49 )	1.54	( 1.53, 1.56 )	1.02	( 0.98, 1.06 )
Acute Lymphocytic Leukemia	0.13	( 0.13, 0.14 )	0.14	( 0.14, 0.15 )	0.08	( 0.07, 0.09 )
Chronic Lymphocytic Leukemia	0.56	( 0.55, 0.57 )	0.59	( 0.58, 0.60 )	0.36	( 0.33, 0.39 )
Acute Myeloid Leukemia	0.46	( 0.46, 0.47 )	0.48	( 0.47, 0.49 )	0.35	( 0.32, 0.37 )
Chronic Myeloid Leukemia	0.18	( 0.18, 0.19 )	0.19	( 0.18, 0.20 )	0.14	( 0.13, 0.16 )
Kaposi Sarcoma	0.05	( 0.04, 0.05 )	0.04	( 0.04, 0.04 )	0.08	( 0.07, 0.09 )
Mesothelioma	0.12	( 0.12, 0.13 )	0.13	( 0.13, 0.14 )	0.06	( 0.05, 0.07 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15 - continued

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 18 SEER Areas, 2010-2012

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	34.50 ( 34.17, 34.85 )	28.75 ( 27.60, 30.00 )	36.25 ( 35.95, 36.56 )
Invasive and In Situ	35.91 ( 35.57, 36.25 )	29.62 ( 28.45, 30.87 )	37.48 ( 37.17, 37.79 )
Oral Cavity and Pharynx	0.89 ( 0.84, 0.95 )	0.89 ( 0.72, 1.18 )	0.79 ( 0.75, 0.84 )
Esophagus	0.33 ( 0.30, 0.38 )	0.27 ( 0.19, 0.50 )	0.37 ( 0.35, 0.41 )
Stomach	1.71 ( 1.63, 1.80 )	1.18 ( 0.95, 1.52 )	1.43 ( 1.37, 1.50 )
Colon and Rectum	4.89 ( 4.76, 5.03 )	4.18 ( 3.74, 4.72 )	4.40 ( 4.29, 4.51 )
Invasive and In Situ	5.05 ( 4.91, 5.19 )	4.26 ( 3.82, 4.81 )	4.53 ( 4.42, 4.65 )
Liver and Intrahepatic Bile Duct	1.87 ( 1.79, 1.95 )	1.38 ( 1.16, 1.71 )	1.61 ( 1.55, 1.67 )
Pancreas	1.65 ( 1.57, 1.74 )	1.25 ( 0.97, 1.65 )	1.59 ( 1.52, 1.66 )
Larynx	0.18 ( 0.16, 0.21 )	0.21 ( 0.13, 0.43 )	0.28 ( 0.25, 0.31 )
Invasive and In Situ	0.20 ( 0.18, 0.24 )	0.22 ( 0.15, 0.45 )	0.30 ( 0.27, 0.33 )
Lung and Bronchus	5.49 ( 5.35, 5.63 )	4.47 ( 4.01, 5.04 )	4.12 ( 4.01, 4.24 )
Melanoma of the Skin	0.16 ( 0.14, 0.19 )	0.39 ( 0.29, 0.63 )	0.51 ( 0.48, 0.55 )
Invasive and In Situ	0.24 ( 0.21, 0.27 )	0.63 ( 0.49, 0.90 )	0.81 ( 0.76, 0.87 )
Breast	5.56 ( 5.44, 5.68 )	4.16 ( 3.77, 4.64 )	5.15 ( 5.04, 5.26 )
Invasive and In Situ	6.87 ( 6.75, 7.00 )	4.78 ( 4.37, 5.27 )	6.04 ( 5.93, 6.15 )
Urinary Bladder (Invasive and In Situ)	1.47 ( 1.39, 1.55 )	1.00 ( 0.77, 1.36 )	1.61 ( 1.54, 1.69 )
Kidney and Renal Pelvis	1.04 ( 0.99, 1.11 )	1.81 ( 1.55, 2.17 )	1.75 ( 1.69, 1.82 )
Brain and Other Nervous System	0.40 ( 0.37, 0.44 )	0.29 ( 0.21, 0.51 )	0.52 ( 0.49, 0.55 )
Thyroid	1.24 ( 1.20, 1.30 )	0.77 ( 0.64, 1.02 )	1.08 ( 1.04, 1.12 )
Hodgkin Lymphoma	0.12 ( 0.11, 0.15 )	0.10 ( 0.05, 0.31 )	0.21 ( 0.19, 0.23 )
Non-Hodgkin Lymphoma	1.84 ( 1.76, 1.92 )	1.26 ( 1.05, 1.57 )	2.18 ( 2.10, 2.25 )
Myeloma	0.54 ( 0.50, 0.59 )	0.54 ( 0.38, 0.82 )	0.79 ( 0.74, 0.84 )
Leukemia	0.99 ( 0.94, 1.06 )	0.81 ( 0.64, 1.10 )	1.22 ( 1.17, 1.28 )
Acute Lymphocytic Leukemia	0.11 ( 0.09, 0.13 )	0.11 ( 0.07, 0.31 )	0.19 ( 0.18, 0.21 )
Chronic Lymphocytic Leukemia	0.18 ( 0.15, 0.21 )	0.20 ( 0.11, 0.45 )	0.30 ( 0.27, 0.33 )
Acute Myeloid Leukemia	0.47 ( 0.43, 0.51 )	0.25 ( 0.16, 0.48 )	0.44 ( 0.40, 0.47 )
Chronic Myeloid Leukemia	0.14 ( 0.12, 0.17 )	0.15 ( 0.09, 0.36 )	0.18 ( 0.16, 0.21 )
Kaposi Sarcoma	0.02 ( 0.01, 0.04 )	0.02 ( 0.00, 0.24 )	0.08 ( 0.07, 0.11 )
Mesothelioma	0.05 ( 0.04, 0.07 )	0.07 ( 0.03, 0.30 )	0.11 ( 0.10, 0.14 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Males, 18 SEER Areas, 2010-2012

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	42.05	( 41.92, 42.18 )	41.71	( 41.56, 41.85 )	40.77	( 40.37, 41.17 )
Invasive and In Situ	43.54	( 43.40, 43.67 )	43.21	( 43.07, 43.36 )	41.10	( 40.70, 41.51 )
Oral Cavity and Pharynx	1.55	( 1.53, 1.58 )	1.62	( 1.59, 1.64 )	1.18	( 1.12, 1.25 )
Esophagus	0.80	( 0.78, 0.82 )	0.84	( 0.82, 0.86 )	0.63	( 0.59, 0.69 )
Stomach	1.07	( 1.05, 1.09 )	0.97	( 0.95, 0.99 )	1.20	( 1.13, 1.28 )
Colon and Rectum	4.69	( 4.65, 4.74 )	4.57	( 4.53, 4.62 )	4.87	( 4.74, 5.02 )
Invasive and In Situ	4.87	( 4.83, 4.92 )	4.74	( 4.70, 4.79 )	5.11	( 4.97, 5.26 )
Liver and Intrahepatic Bile Duct	1.31	( 1.28, 1.33 )	1.16	( 1.14, 1.19 )	1.45	( 1.39, 1.52 )
Pancreas	1.54	( 1.51, 1.56 )	1.54	( 1.51, 1.57 )	1.49	( 1.41, 1.57 )
Larynx	0.59	( 0.57, 0.60 )	0.59	( 0.57, 0.60 )	0.75	( 0.70, 0.81 )
Invasive and In Situ	0.63	( 0.61, 0.64 )	0.63	( 0.61, 0.64 )	0.79	( 0.74, 0.85 )
Lung and Bronchus	7.19	( 7.14, 7.24 )	7.20	( 7.14, 7.26 )	7.52	( 7.34, 7.70 )
Melanoma of the Skin	2.62	( 2.58, 2.65 )	3.03	( 2.99, 3.07 )	0.10	( 0.08, 0.12 )
Invasive and In Situ	4.37	( 4.33, 4.41 )	4.94	( 4.89, 4.98 )	0.13	( 0.11, 0.16 )
Breast	0.13	( 0.12, 0.14 )	0.13	( 0.12, 0.14 )	0.16	( 0.14, 0.19 )
Invasive and In Situ	0.14	( 0.14, 0.15 )	0.14	( 0.13, 0.15 )	0.18	( 0.16, 0.21 )
Prostate	13.97	( 13.89, 14.04 )	13.15	( 13.07, 13.23 )	18.15	( 17.90, 18.41 )
Testis	0.38	( 0.38, 0.39 )	0.46	( 0.44, 0.47 )	0.10	( 0.09, 0.12 )
Urinary Bladder (Invasive and In Situ)	3.84	( 3.80, 3.88 )	4.16	( 4.12, 4.21 )	1.86	( 1.77, 1.96 )
Kidney and Renal Pelvis	2.03	( 2.01, 2.06 )	2.09	( 2.06, 2.12 )	1.96	( 1.88, 2.04 )
Brain and Other Nervous System	0.69	( 0.68, 0.71 )	0.76	( 0.74, 0.78 )	0.40	( 0.36, 0.44 )
Thyroid	0.59	( 0.58, 0.60 )	0.63	( 0.62, 0.65 )	0.27	( 0.25, 0.31 )
Hodgkin Lymphoma	0.24	( 0.23, 0.25 )	0.25	( 0.24, 0.26 )	0.21	( 0.19, 0.24 )
Non-Hodgkin Lymphoma	2.37	( 2.34, 2.40 )	2.47	( 2.44, 2.51 )	1.43	( 1.36, 1.50 )
Myeloma	0.85	( 0.84, 0.87 )	0.81	( 0.79, 0.83 )	1.33	( 1.26, 1.41 )
Leukemia	1.75	( 1.73, 1.78 )	1.84	( 1.81, 1.87 )	1.14	( 1.07, 1.21 )
Acute Lymphocytic Leukemia	0.14	( 0.14, 0.15 )	0.16	( 0.15, 0.16 )	0.08	( 0.07, 0.10 )
Chronic Lymphocytic Leukemia	0.69	( 0.67, 0.71 )	0.73	( 0.71, 0.74 )	0.43	( 0.39, 0.49 )
Acute Myeloid Leukemia	0.53	( 0.52, 0.55 )	0.55	( 0.53, 0.57 )	0.36	( 0.32, 0.40 )
Chronic Myeloid Leukemia	0.22	( 0.21, 0.23 )	0.23	( 0.22, 0.24 )	0.15	( 0.12, 0.17 )
Kaposi Sarcoma	0.08	( 0.07, 0.08 )	0.06	( 0.06, 0.07 )	0.16	( 0.14, 0.18 )
Mesothelioma	0.20	( 0.19, 0.21 )	0.22	( 0.21, 0.23 )	0.09	( 0.07, 0.12 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 18 SEER Areas, 2010-2012

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	36.15 ( 35.64, 36.68 )	28.31 ( 26.68, 30.15 )	38.84 ( 38.37, 39.33 )
Invasive and In Situ	36.48 ( 35.97, 37.01 )	28.61 ( 26.97, 30.46 )	39.29 ( 38.81, 39.78 )
Oral Cavity and Pharynx	1.21 ( 1.12, 1.31 )	1.37 ( 1.05, 1.95 )	1.12 ( 1.05, 1.21 )
Esophagus	0.55 ( 0.48, 0.63 )	0.42 ( 0.27, 0.91 )	0.62 ( 0.57, 0.69 )
Stomach	2.05 ( 1.92, 2.20 )	1.43 ( 1.06, 2.07 )	1.70 ( 1.60, 1.82 )
Colon and Rectum	5.27 ( 5.07, 5.48 )	4.42 ( 3.80, 5.26 )	4.72 ( 4.56, 4.90 )
Invasive and In Situ	5.44 ( 5.24, 5.65 )	4.48 ( 3.86, 5.33 )	4.87 ( 4.71, 5.05 )
Liver and Intrahepatic Bile Duct	2.56 ( 2.43, 2.70 )	1.76 ( 1.40, 2.37 )	2.25 ( 2.15, 2.37 )
Pancreas	1.58 ( 1.48, 1.70 )	1.20 ( 0.84, 1.85 )	1.50 ( 1.40, 1.62 )
Larynx	0.33 ( 0.28, 0.40 )	0.33 ( 0.20, 0.81 )	0.53 ( 0.47, 0.60 )
Invasive and In Situ	0.38 ( 0.32, 0.45 )	0.36 ( 0.22, 0.83 )	0.56 ( 0.50, 0.63 )
Lung and Bronchus	6.81 ( 6.57, 7.05 )	4.85 ( 4.16, 5.78 )	4.80 ( 4.61, 5.01 )
Melanoma of the Skin	0.20 ( 0.17, 0.26 )	0.29 ( 0.17, 0.77 )	0.51 ( 0.46, 0.58 )
Invasive and In Situ	0.30 ( 0.25, 0.37 )	0.50 ( 0.33, 0.99 )	0.80 ( 0.73, 0.89 )
Breast	0.08 ( 0.06, 0.13 )	0.03 ( 0.01, 0.50 )	0.08 ( 0.06, 0.12 )
Invasive and In Situ	0.09 ( 0.07, 0.14 )	0.05 ( 0.02, 0.53 )	0.09 ( 0.07, 0.13 )
Prostate	9.39 ( 9.15, 9.64 )	6.53 ( 5.81, 7.48 )	12.96 ( 12.71, 13.22 )
Testis	0.15 ( 0.13, 0.18 )	0.32 ( 0.24, 0.76 )	0.35 ( 0.33, 0.39 )
Urinary Bladder (Invasive and In Situ)	2.34 ( 2.20, 2.50 )	1.67 ( 1.21, 2.42 )	2.58 ( 2.44, 2.74 )
Kidney and Renal Pelvis	1.39 ( 1.30, 1.49 )	2.21 ( 1.83, 2.83 )	2.14 ( 2.03, 2.25 )
Brain and Other Nervous System	0.45 ( 0.40, 0.52 )	0.35 ( 0.24, 0.81 )	0.55 ( 0.51, 0.61 )
Thyroid	0.61 ( 0.56, 0.68 )	0.35 ( 0.24, 0.81 )	0.48 ( 0.44, 0.53 )
Hodgkin Lymphoma	0.14 ( 0.12, 0.18 )	0.10 ( 0.04, 0.57 )	0.23 ( 0.20, 0.28 )
Non-Hodgkin Lymphoma	2.09 ( 1.98, 2.23 )	1.37 ( 1.05, 1.95 )	2.39 ( 2.28, 2.51 )
Myeloma	0.62 ( 0.55, 0.70 )	0.49 ( 0.28, 1.03 )	0.93 ( 0.85, 1.02 )
Leukemia	1.20 ( 1.11, 1.31 )	0.90 ( 0.64, 1.45 )	1.40 ( 1.31, 1.51 )
Acute Lymphocytic Leukemia	0.13 ( 0.11, 0.17 )	0.09 ( 0.05, 0.56 )	0.19 ( 0.18, 0.23 )
Chronic Lymphocytic Leukemia	0.27 ( 0.22, 0.34 )	0.20 ( 0.07, 0.70 )	0.36 ( 0.31, 0.43 )
Acute Myeloid Leukemia	0.52 ( 0.46, 0.59 )	0.29 ( 0.17, 0.77 )	0.49 ( 0.43, 0.56 )
Chronic Myeloid Leukemia	0.19 ( 0.16, 0.24 )	0.16 ( 0.07, 0.63 )	0.21 ( 0.18, 0.26 )
Kaposi Sarcoma	0.04 ( 0.03, 0.07 )	0.04 ( 0.00, 0.52 )	0.11 ( 0.09, 0.16 )
Mesothelioma	0.08 ( 0.06, 0.13 )	0.16 ( 0.06, 0.64 )	0.18 ( 0.16, 0.24 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 18 SEER Areas, 2010-2012

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	37.58	( 37.47, 37.70 )	38.25	( 38.12, 38.38 )	34.30	( 33.96, 34.64 )
Invasive and In Situ	40.80	( 40.68, 40.92 )	41.49	( 41.35, 41.62 )	36.56	( 36.21, 36.90 )
Oral Cavity and Pharynx	0.67	( 0.66, 0.69 )	0.69	( 0.68, 0.71 )	0.48	( 0.45, 0.52 )
Esophagus	0.22	( 0.21, 0.23 )	0.22	( 0.21, 0.23 )	0.26	( 0.24, 0.30 )
Stomach	0.66	( 0.65, 0.68 )	0.56	( 0.54, 0.58 )	0.94	( 0.88, 1.00 )
Colon and Rectum	4.35	( 4.31, 4.39 )	4.25	( 4.21, 4.30 )	4.68	( 4.55, 4.81 )
Invasive and In Situ	4.49	( 4.45, 4.53 )	4.39	( 4.34, 4.43 )	4.86	( 4.73, 4.99 )
Liver and Intrahepatic Bile Duct	0.54	( 0.53, 0.56 )	0.47	( 0.46, 0.49 )	0.51	( 0.47, 0.56 )
Pancreas	1.50	( 1.48, 1.53 )	1.47	( 1.44, 1.49 )	1.71	( 1.63, 1.79 )
Larynx	0.13	( 0.13, 0.14 )	0.14	( 0.13, 0.14 )	0.17	( 0.15, 0.20 )
Invasive and In Situ	0.14	( 0.14, 0.15 )	0.15	( 0.14, 0.15 )	0.18	( 0.16, 0.21 )
Lung and Bronchus	6.04	( 5.99, 6.09 )	6.31	( 6.26, 6.36 )	5.40	( 5.26, 5.54 )
Melanoma of the Skin	1.63	( 1.61, 1.66 )	1.93	( 1.90, 1.95 )	0.11	( 0.10, 0.14 )
Invasive and In Situ	2.82	( 2.79, 2.85 )	3.24	( 3.21, 3.28 )	0.15	( 0.13, 0.18 )
Breast	12.32	( 12.26, 12.39 )	12.64	( 12.57, 12.71 )	11.14	( 10.97, 11.33 )
Invasive and In Situ	14.67	( 14.60, 14.73 )	14.96	( 14.89, 15.04 )	13.37	( 13.18, 13.57 )
Cervix Uteri	0.64	( 0.62, 0.65 )	0.62	( 0.61, 0.64 )	0.77	( 0.73, 0.82 )
Corpus and Uterus, NOS	2.78	( 2.75, 2.81 )	2.86	( 2.83, 2.89 )	2.53	( 2.45, 2.62 )
Invasive and In Situ	2.80	( 2.77, 2.83 )	2.88	( 2.85, 2.92 )	2.56	( 2.47, 2.65 )
Ovary <sup>a</sup>	1.31	( 1.29, 1.33 )	1.37	( 1.35, 1.40 )	0.99	( 0.93, 1.05 )
Urinary Bladder (Invasive and In Situ)	1.14	( 1.12, 1.16 )	1.21	( 1.19, 1.24 )	0.81	( 0.75, 0.87 )
Kidney and Renal Pelvis	1.20	( 1.18, 1.22 )	1.24	( 1.21, 1.26 )	1.26	( 1.20, 1.33 )
Brain and Other Nervous System	0.54	( 0.53, 0.55 )	0.60	( 0.58, 0.61 )	0.32	( 0.29, 0.35 )
Thyroid	1.72	( 1.70, 1.74 )	1.81	( 1.79, 1.84 )	1.02	( 0.98, 1.07 )
Hodgkin Lymphoma	0.20	( 0.19, 0.20 )	0.21	( 0.20, 0.22 )	0.18	( 0.16, 0.20 )
Non-Hodgkin Lymphoma	1.89	( 1.87, 1.92 )	1.99	( 1.96, 2.02 )	1.19	( 1.13, 1.26 )
Myeloma	0.64	( 0.62, 0.65 )	0.57	( 0.55, 0.58 )	1.23	( 1.17, 1.30 )
Leukemia	1.22	( 1.20, 1.24 )	1.28	( 1.26, 1.30 )	0.92	( 0.86, 0.98 )
Acute Lymphocytic Leukemia	0.12	( 0.11, 0.12 )	0.13	( 0.13, 0.14 )	0.07	( 0.06, 0.09 )
Chronic Lymphocytic Leukemia	0.44	( 0.43, 0.45 )	0.47	( 0.46, 0.49 )	0.30	( 0.26, 0.33 )
Acute Myeloid Leukemia	0.41	( 0.39, 0.42 )	0.42	( 0.40, 0.43 )	0.34	( 0.30, 0.37 )
Chronic Myeloid Leukemia	0.15	( 0.14, 0.16 )	0.15	( 0.14, 0.16 )	0.14	( 0.12, 0.16 )
Kaposi Sarcoma	0.01	( 0.01, 0.02 )	0.01	( 0.01, 0.02 )	0.01	( 0.01, 0.02 )
Mesothelioma	0.05	( 0.05, 0.06 )	0.06	( 0.05, 0.06 )	0.03	( 0.02, 0.04 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Females, 18 SEER Areas, 2010-2012

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	33.28 ( 32.83, 33.73 )	29.40 ( 27.77, 31.21 )	34.38 ( 33.99, 34.79 )
Invasive and In Situ	35.62 ( 35.17, 36.08 )	30.83 ( 29.18, 32.66 )	36.36 ( 35.95, 36.77 )
Oral Cavity and Pharynx	0.63 ( 0.56, 0.70 )	0.45 ( 0.31, 0.87 )	0.49 ( 0.45, 0.55 )
Esophagus	0.15 ( 0.12, 0.20 )	0.13 ( 0.06, 0.54 )	0.16 ( 0.13, 0.20 )
Stomach	1.43 ( 1.32, 1.55 )	0.97 ( 0.70, 1.48 )	1.21 ( 1.13, 1.30 )
Colon and Rectum	4.57 ( 4.39, 4.77 )	3.96 ( 3.34, 4.79 )	4.11 ( 3.96, 4.26 )
Invasive and In Situ	4.72 ( 4.53, 4.91 )	4.06 ( 3.43, 4.90 )	4.23 ( 4.08, 4.39 )
Liver and Intrahepatic Bile Duct	1.29 ( 1.19, 1.39 )	1.03 ( 0.77, 1.53 )	1.03 ( 0.96, 1.11 )
Pancreas	1.71 ( 1.59, 1.83 )	1.29 ( 0.89, 1.95 )	1.66 ( 1.57, 1.77 )
Larynx	0.06 ( 0.04, 0.09 )	0.08 ( 0.03, 0.49 )	0.07 ( 0.05, 0.10 )
Invasive and In Situ	0.06 ( 0.04, 0.10 )	0.10 ( 0.03, 0.50 )	0.07 ( 0.06, 0.10 )
Lung and Bronchus	4.41 ( 4.25, 4.59 )	4.16 ( 3.55, 4.98 )	3.61 ( 3.47, 3.75 )
Melanoma of the Skin	0.13 ( 0.11, 0.17 )	0.49 ( 0.33, 0.92 )	0.52 ( 0.47, 0.58 )
Invasive and In Situ	0.18 ( 0.15, 0.22 )	0.75 ( 0.54, 1.22 )	0.84 ( 0.77, 0.91 )
Breast	10.25 ( 10.05, 10.47 )	8.15 ( 7.41, 9.08 )	9.81 ( 9.62, 10.01 )
Invasive and In Situ	12.70 ( 12.47, 12.94 )	9.36 ( 8.59, 10.32 )	11.54 ( 11.34, 11.75 )
Cervix Uteri	0.64 ( 0.59, 0.71 )	0.58 ( 0.44, 0.98 )	0.90 ( 0.85, 0.96 )
Corpus and Uterus, NOS	2.25 ( 2.15, 2.35 )	1.93 ( 1.62, 2.45 )	2.42 ( 2.33, 2.52 )
Invasive and In Situ	2.26 ( 2.17, 2.37 )	1.96 ( 1.65, 2.48 )	2.43 ( 2.35, 2.53 )
Ovary <sup>c</sup>	1.08 ( 1.01, 1.16 )	1.16 ( 0.84, 1.73 )	1.29 ( 1.22, 1.37 )
Urinary Bladder (Invasive and In Situ)	0.75 ( 0.67, 0.85 )	0.42 ( 0.26, 0.86 )	0.80 ( 0.73, 0.88 )
Kidney and Renal Pelvis	0.76 ( 0.69, 0.84 )	1.44 ( 1.10, 2.00 )	1.42 ( 1.34, 1.50 )
Brain and Other Nervous System	0.35 ( 0.31, 0.41 )	0.22 ( 0.12, 0.63 )	0.48 ( 0.44, 0.53 )
Thyroid	1.81 ( 1.73, 1.90 )	1.18 ( 0.96, 1.64 )	1.67 ( 1.61, 1.75 )
Hodgkin Lymphoma	0.11 ( 0.09, 0.14 )	0.10 ( 0.04, 0.50 )	0.18 ( 0.16, 0.22 )
Non-Hodgkin Lymphoma	1.63 ( 1.53, 1.74 )	1.16 ( 0.90, 1.66 )	1.99 ( 1.89, 2.10 )
Myeloma	0.48 ( 0.43, 0.55 )	0.59 ( 0.38, 1.07 )	0.67 ( 0.62, 0.74 )
Leukemia	0.82 ( 0.74, 0.90 )	0.74 ( 0.52, 1.20 )	1.07 ( 1.00, 1.15 )
Acute Lymphocytic Leukemia	0.09 ( 0.07, 0.12 )	0.12 ( 0.07, 0.51 )	0.18 ( 0.16, 0.21 )
Chronic Lymphocytic Leukemia	0.11 ( 0.08, 0.14 )	0.21 ( 0.10, 0.64 )	0.25 ( 0.21, 0.29 )
Acute Myeloid Leukemia	0.43 ( 0.38, 0.49 )	0.20 ( 0.09, 0.62 )	0.40 ( 0.36, 0.45 )
Chronic Myeloid Leukemia	0.11 ( 0.08, 0.15 )	0.14 ( 0.07, 0.53 )	0.15 ( 0.12, 0.19 )
Kaposi Sarcoma	0.00 ( 0.00, 0.03 )	0.01 ( 0.00, 0.43 )	0.05 ( 0.03, 0.09 )
Mesothelioma	0.03 ( 0.02, 0.06 )	0.00 ( 0.00, 0.42 )	0.05 ( 0.04, 0.08 )

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>c</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.